Evidence map›Paper›PMID 35323052›Full record

Trial reportJournal of applied physiology (Bethesda, Md. : 1985)2022

A randomized, crossover, placebo controlled, double-blind trial of the effects of tiotropium-olodaterol on neuromuscular performance during exercise in COPD.

Min Cao, Robert A Calmelat, Peter Kierstead, Nicolo Carraro, William W Stringer, Janos Porszasz, Richard Casaburi, Harry B Rossiter

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of applied physiology (Bethesda, Md. : 1985), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Min CaoRehabilitation Clinical Trials Center, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.
Robert A CalmelatRehabilitation Clinical Trials Center, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.
Peter KiersteadAntioch Medical Center, Pulmonary Medicine, Antioch, California.
Nicolo CarraroHigh Specialization Rehabilitation Hospital, ORAS, Motta di Livenza, Italy.
William W StringerRehabilitation Clinical Trials Center, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.ORCID 0000-0003-2756-6728
Janos PorszaszRehabilitation Clinical Trials Center, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.
Richard CasaburiRehabilitation Clinical Trials Center, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.
Harry B RossiterRehabilitation Clinical Trials Center, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.ORCID 0000-0002-7884-0726
UCLA Medical Center · USAntioch University · USCapital Medical University · CN

Funding

Mechanism Underlying the Transduction of Epimutations from the Soma to the Male GermlineP50HD098593 · NICHD · UNIVERSITY OF NEVADA RENO · PI YAN, WEI · 2019 to 2024
$7.2M
Rehabilitation Research Resource to Enhance Clinical Trials (ReACT)P2CHD086851 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BAMMAN, MARCAS M · 2015 to 2019
$7.1M
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis PatientsR01DK122767 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RHEE, CONNIE MEEYOUNG · 2019 to 2023
$3.3M
Determinants of 5 Year Progression of Muscle Dysfunction and Inactivity in COPDGene Participants Diversity SupplementR01HL151452 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI ADAMI, ALESSANDRA, ROSSITER, HARRY B · 2020 to 2023
$1.6M
Boehringer Ingelheim (BI)HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) P2CHD086851NHLBI NIH HHS R01 HL151452NICHD NIH HHS P2C HD086851NICHD NIH HHS P50 HD098593NIDDK NIH HHS R01 DK122767UC | Office of the President, University of California (UCOP) T31IP1666
6 · The paper itself

Abstract

Exercise intolerance in chronic obstructive pulmonary disease (COPD) is associated with dyspnea, reduced inspiratory capacity (IC) and occurs with a neuromuscular "power reserve," i.e., an acute ability to increase isokinetic locomotor power. This power reserve is associated with resting forced expiratory volume in 1 s (FEV

Indexed as

Bronchodilator AgentsPulmonary Disease, Chronic ObstructiveBenzoxazinesCross-Over StudiesDrug CombinationsFatigueFemaleHumansMaleMuscarinic AntagonistsTiotropium BromideBenzoxazinesBronchodilator AgentsDrug CombinationsMuscarinic AntagonistsTiotropium Bromidetiotropium-olodaterolbronchodilationdynamic hyperinflationexercise intolerancefatigueisokinetic dynamometry

Identifiers

PMID35323052
PMCPMC9054255
OpenAlexW4220962157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.